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Introduction 
Chronic non-cancer pain is a common cause of disability worldwide. The Global Burden of 
Disease (GBD) 2010 study 1 estimated that in 2010, 1·0 billion people (15% of world 
population) had migraines, 630 million (9%) had lower back pain, and 332 million (5%) had 
neck pain. Low back pain, neck pain, and migraines were the ﬁrst, fourth, and eighth largest 
contributors, respectively, to global non-fatal health burden (years lived with disability).1 
Chronic non-cancer pain can also have a major eﬀect on social and ﬁnancial well-being, and 
increases health costs. 2,3 The burden of chronic pain will probably increase in the future as 
the population ages in many high-income countries. 
Despite little evidence for eﬃcacy in use of long-term opioids to manage chronic non-cancer 
pain,4–6 rates of prescription have increased in many high-income countries, including the 
USA, Canada, and Australia. 7–11 
Concern has also been rising about concomitant increases in problematic use of, and 
dependence upon, these opioids. 12,13 The two major classiﬁcation systems for disorders of 
opioid use have been undergoing revision. WHO’s tenth edition of ICD (ICD-10) distinguishes 
between harmful use (deﬁned as a pattern of use of a psychoactive substance that is 
causing damage to physical or mental health) and dependence (a cluster of symptoms that 
typically include craving, diﬃculties in controlling use, persisting use despite adverse 
consequences, tolerance, and withdrawal). 14 In the specialty of pain medicine, dependence 
is often referred to as addiction,15 with less emphasis upon tolerance and withdrawal, 
which are considered to be physiological results of long-term opioid use and not markers of 
problematic use. The eleventh edition of ICD (ICD-11) is planned to be presented to the 
World Health Assembly in May, 2017. 16 The beta version of ICD-11 draft descriptions and 
clinical features of disorders were released in July, 2014. The draft proposal for substance 
dependence has retained the concept of a dependence syndrome, but proposes that criteria 
(or features) should be reduced to three (from six) and that to meet criteria for dependence, 
an individual needs to meet only two. 
DSM-5 was released on May 18, 2013, by the American Psychiatric Association.17 The 
previous edition, DSM-IV, deﬁned opioid abuse and opioid dependence18 in broadly similar 
ways to the terms used in ICD-10. By contrast, DSM-5 shifted to classiﬁcations of opioid use 
disorders (divided into mild, moderate, and severe based on number of symptoms).17 11 
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criteria are included; a person who fulﬁls at least two of these meets the deﬁnition for a use 
disorder. Tolerance and withdrawal are included, but a person taking opioids only under 
medical supervision (and not being non-adherent—eg, doctor shopping, tapering, diverting, 
or taking more opioids than directed) is not thought, in DSM-5, to fulﬁl either criteria (which 
we describe as conditional exclusion),17 in keeping with the view of pain physicians that 
under chronic administration of opioids, the development of tolerance and withdrawal is 
expected. The shifts in DSM-5 have not been without controversy.19–29 Questions have 
been raised about the validity of the new deﬁnition, the adequacy of ﬁeld testing,21 the 
potential cultural and social biases embodied in the new approach,20 and the clinical and 
epidemiological eﬀects of the lowered diagnostic thresholds.22,30,31 Other people have 
questioned the clinical use of the combined diagnosis of use disorders, which no longer 
distinguishes between episodic binge use and compulsive use.22 Some have questioned 
their use in cases in which doctors might be legally mandated to provide treatment if that 
person is not formally assessed as dependent. 
Less has been written about the eﬀect of these diﬀering approaches to classiﬁcation of 
people taking opioids for chronic non-cancer pain. Signiﬁcant debate exists about when and 
how a diagnosis of opioid dependence can or should be made in persons receiving long-
term opioid treatment for chronic non-cancer pain.32,33 Some investigators suggest that 
dependence and addiction should be considered separately in this population.26,27,34–36 
Behaviours that are suggestive of dependence symptoms might arise for many reasons. For 
example, requests for increased doses could be due to undertreatment of pain, tolerance, 
or drug seeking (as a symptom of dependent use).37,38 Some investigators have questioned 
the relevance of these diagnostic criteria in older adults,39 in whom chronic pain is more 
prevalent. Absences from work or school; less frequent car or machine operation; and a 
general reduction in social, occupational, and recreational activities are common in patients 
with chronic pain. This can make it diﬃcult to assess some of the diagnostic criteria in older 
adults. Additionally, approaches vary for the inclusion of tolerance and withdrawal in the 
diagnosis of opioid dependence in patients receiving opioids for chronic non-cancer pain. 
In this study, we aim to compare how the diﬀerent operational approaches to 
pharmaceutical opioid use disorder or dependence classify individuals in a large, national, 
community-based sample of people living with non-cancer chronic pain who have been 
prescribed opioids to manage their pain. Speciﬁcally, we aim to estimate the prevalence of 
pharmaceutical opioid dependence and opioid use disorder in a cohort of patients using 
opioids chronically with the criteria in DSM-IV, DSM-5, ICD-10, and draft ICD-11 criteria; 
assess criteria fulﬁlled by those meeting each deﬁnition of a disorder; investigate 
concordance between the deﬁnitions; and assess the extent to which the criteria of the 
varying deﬁnitions describe a unidimensional syndrome. 
 
Methods 
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Study design and setting 
We studied patients enrolled in the Pain and Opioid IN Treatment (POINT) cohort. This 
cohort was recruited to document patterns of pharmaceutical opioid use and the risk of 
adverse events in a prospective cohort of patients who were prescribed opioids for chronic 
non- cancer pain. The POINT cohort was established in 2012. We contacted 90% of all 
community pharmacies in Australia (n=5332) and asked if they would assist with 
recruitment; 33% (n=1868) agreed to assist. The cohort includes 1514 community-based 
patients with chronic non-cancer pain. The methodology of this cohort has been described 
in detail elsewhere.40 POINT participants were aged 18 years or older; competent in 
English; mentally and physically able to complete the required interviews; without serious 
cognitive impairments as assessed by interviews (not a formal clinical assessment); and 
prescribed a schedule 8 strong opioid for non- cancer pain for longer than 6 weeks (eg, 
oxycodone, fentanyl). A history of injection drug use was not an exclusion criterion for 
POINT, but patients prescribed pharmaceutical opioids for opioid substitution therapy for 
heroin dependence or who were taking opioids for cancer pain were not eligible. The study 
was approved by the Human Research Ethics Committee of University of New South Wales 
Australia (HREC reference: HC12149). 
 
Procedures 
We assessed disorders of pharmaceutical opioid use with the Composite International 
Diagnostic Interview (CIDI) version 3.0.41 CIDI has been used widely in epidemiological 
studies in many countries,42–45 and has excellent inter-rater reliability,41 test–retest 
reliability,41 and agreement with clinician diagnoses.46 Phone interviews were done by 
trained interviewers who had received training in a computer-assisted telephone 
interviewing survey during 
Table 1: Criteria included in classiﬁcation systems and number of participants in the POINT 
cohort that meet criteria 
the baseline interviews with cohort participants. Inter- viewers had a health or psychology 
degree of duration 3 years or longer, were trained in how to respond to reports of suicidal 
thoughts or suicidal plans, and were provided with glossaries of chronic pain drugs and 
disorders. We assessed patients with ICD and DSM opioid use disorder criteria. 
 
Statistical analysis 
We included all POINT members who completed the CIDI. The frequency of participants 
meeting each criterion for pharmaceutical opioid use disorder and dependence according to 
the four classiﬁcation systems was reported. We examined the agreement between 
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numbers of participants meeting criteria for each deﬁnition of disorder. We used binary 
conﬁrmatory 
factor analyses to test the ﬁt of a unifactorial model of dependence (consistent with those 
found for all other substances of dependence47,48) within each deﬁnition of dependence or 
disorder. We applied robust maximum likelihood techniques in Mplus 7.2 (Los Angeles, CA, 
USA). In addition, we replicated analyses with use of the mean and variance-adjusted 
weighted least-squares extraction procedure for estimation. We examined model-ﬁt indices 
of root mean square residual (RMSEA), weighted root mean square residual (WRMR), and 
comparative ﬁt index (CFI). For categorical data, values of RMSEA less than 0·06, WRMR less 
than 0·90, Tucker–Lewis Index (TLI) greater than 0·96, and CFI greater than 0·95 indicate 
good model ﬁt.49 We compared the binary conﬁrmatory factor values of each model, with 
lower values indicating a better ﬁt.50 
  
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had ﬁnal responsibility for the decision to submit for publication 
 
Results 
Of 1422 participants who completed CIDI assessment, 790 (56%) were women; median age 
58 years (IQR 48–67). 
Almost half (695; 49%) were unemployed, 499 (35%) had completed tertiary qualiﬁcations, 
and 760 (53%) were married or in a de-facto relationship. The full demographic, physical, 
and mental health characteristics of this cohort are detailed by Campbell and colleagues.51 
Participants reported living with their current pain disorder for a median of 10 years (IQR 5–
20). Median length of strong opioid prescription was 4·0 years (IQR 1·5–10·0). The most 
common opioids reported were oxycodone (862; 61%), buprenorphine (310; 22%), 
morphine (212; 15%), and fentanyl (211; 15%). Patients were taking a median of one 
schedule eight opioid (IQR 1·0–1·0). 
Very similar proportions of participants met lifetime criteria for dependence (table 1) when 
assessed with DSM-IV (127; 8·9% [95% CI 7·5–10·5]), ICD-10 (121; 8·5% [7·2–10·1]), and ICD-
11 (141; 9·9% [8·5–11·6]) 
classiﬁcation systems (table 2). For DSM-IV and ICD-10, slightly less than one in ﬁve people 
met criteria for a disorder of pharmaceutical opioid use (table 2). 
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Prevalence of use disorder as described in DSM-5 was considerably higher than that of 
opioid dependence as deﬁned by the other three methods and was higher than use disorder 
as described by DSM-IV and ICD-10 (table 2). One in ﬁve (293; 20·8% [95% CI 18·8–23·0]) 
people in the cohort met DSM-5 criteria for pharmaceutical opioid use disorder with its 
standard deﬁnition in which tolerance and withdrawal do not count as symptoms of use 
disorder unless the person is non-adherent with their opioids (conditional exclusion). One in 
20 patients (67; 4·8% [95% CI 3·8–6·0] were classiﬁed as having severe opioid use disorder 
with DSM-5. When tolerance and withdrawal were included as symptoms of use disorder 
(irrespective of the adherence), numbers increased to 414 (29% [95% CI 27·1–31·8]) overall 
and 88 (6·3% [5·1–7·6]) with a severe use disorder (table 2). More men than women were 
classiﬁed as having use disorder with ICD-10, DSM-IV, and DSM-5, and more men than 
women were dependent according to ICD-10, ICD-11, and DSM-IV (table 2). There were no 
gender diﬀerences in frequencies of people classiﬁed as having DSM-IV abuse or ICD-10 
harmful use (table 2). 
There were substantial diﬀerences between the deﬁnitions of disorders in the proportion of 
patients meeting speciﬁc criteria (table 3; appendix). In general, people meeting criteria for 
DSM-5 use disorder as a group had lower prevalences of each individual criterion. Those 
meeting ICD-11 dependence had the highest prevalences 
of each individual criterion. This reﬂected the fact that ICD-11 had only three criteria, each 
of which included up to four of DSM-5 individual criteria. Compared with individuals 
meeting criteria for dependence with ICD-11, ICD-10 and DSM-IV, those meeting criteria for 
either DSM-5 use disorder (ie, with or without the conditional exclusion of tolerance and 
withdrawal) had much lower prevalence of the following criteria: used in larger amounts or 
longer than intended, great deal of time spent using and recovering from use, continued use 
despite recurrent social and interpersonal problems due to use, and tolerance. 
The most inclusive deﬁnition of use disorder was DSM-5 including tolerance and withdrawal 
(appendix). An additional 121 (8%) people met criteria when there was no conditional 
exclusion of tolerance and withdrawal as criteria, with 14 (1%) reporting no symptoms other 
than tolerance and withdrawal and 107 (7%) reporting only one other symptom. 
No combination of ICD-11 with any level of DSM-5 (mild, moderate, or severe) showed 
excellent agreement with DSM-5 use disorder (as measured with κ; appendix).52 Agreement 
between the DSM-5 disorder with and without the conditional exclusion of tolerance and 
withdrawal was good (κ=0·77; appendix). Agreement for any DSM-5 opioid use disorder 
(with conditional exclusions) ranged from κ=0·49 (with ICD-10) to κ=0·56 (ICD-11). 
Agreement was much poorer for DSM-5 when no restrictions were put on tolerance and 
withdrawal as criteria (κ=0·37–0·42). The highest κ values for DSM-5 classiﬁed severe use 
disorder were for ICD-10 (κ=0·69) and DSM-IV dependence (κ=0·67) 
5 
 
Author postprint of Degenhardt, L., …., Hall, W., … & Campbell, G. (2015). Agreement 
between definitions of pharmaceutical opioid use disorders and dependence in people 
taking opioids for chronic non-cancer pain (POINT): a cohort study. Lancet Psychiatry, 2, 314-
22. 10.1016/s2215-0366(15)00005-x. Please refer to published version for tables. 
 
without imposing conditional exclusion of tolerance and withdrawal as criteria. Agreement 
was similar for the deﬁnition of DSM-5 severe use disorder that had conditional exclusion of 
tolerance and withdrawal (appendix). 
When we grouped together individuals classiﬁed as having moderate or severe use disorder 
by DSM-5, there was still only middling agreement with ICD deﬁnitions and discrepancies in 
the classiﬁcation of cases were more marked (appendix). A quarter (25%) and a third (34%) 
of those classiﬁed as dependent under ICD-10 and ICD-11 deﬁnitions, respectively, did not 
meet criteria for moderate or severe use disorder in DSM-5; almost three in ten of those 
classiﬁed as dependent under the DSM-IV deﬁnition were not classiﬁed as meeting criteria 
for moderate or severe DSM-5 use disorder (without conditional exclusion of tolerance and 
withdrawal; appendix). 
The classiﬁcation resulting in the greatest number of people being identiﬁed with 
dependence was ICD-11, followed by DSM-IV and ICD-10. Nonetheless, there was almost 
perfect agreement between ICD-10, ICD-11, and DSM-IV dependence, with the κ coeﬃcient 
for all pairs of these classiﬁcations greater than 0·90. 
Criteria for all deﬁnitions loaded well on a single factor (appendix). Generally, the items that 
loaded most strongly on the single factor were the psychological or behavioural symptoms 
of dependence or addiction, rather than the physiological ones, although all loadings were 
relatively high. According to model ﬁt statistics, the best model was for the deﬁnition of 
dependence in the draft ICD-11, and the worst ﬁt was for DSM-5 
(appendix). The model ﬁt was slightly better for DSM-5 with conditional exclusion (ie, the 
published deﬁnition) than for DSM-5 without conditional exclusion of tolerance and 
withdrawal. 
 
Discussion 
We assessed how diﬀerent diagnostic classiﬁcation systems identify disorders of 
pharmaceutical opioid use among people prescribed opioids for chronic non-cancer pain. 
Application of the criteria for DSM-5 produced much higher estimates of pharmaceutical 
opioid use disorders, and did not have very good agreement with both DSM-IV and with 
ICD-10 and ICD-11. Of the systems, the model ﬁt statistics for DSM-5 were also the poorest, 
although still adequate. By contrast, dependence deﬁned by ICD-11 had the best model ﬁt 
statistics, and showed excellent agreement with the two previous classiﬁcations (DSM-IV 
and ICD-10). 
There is considerable debate about how to identify problematic use of opioids in people 
who are receiving long-term opioids for medical purposes. The changes to DSM that 
occurred with DSM-5, which applied conditional exclusion of tolerance and withdrawal 
when drugs are used only as intended under medical supervision, were intended to avoid 
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misclassiﬁcation of patients as dependent only because of normal physiological adaptations 
to long-term opioid use.36 We did ﬁnd sizeable diﬀerences in proportions of people with 
opioid use disorder according to whether these conditional exclusions were in place (by 
contrast with previous research53). The model ﬁt was slightly better for the deﬁnition that 
had conditional exclusion of tolerance and withdrawal. The eﬀect of excluding these 
patients in the DSM-5 deﬁnition was most apparent in those who either were non-cases 
when exclusions were in place (increase of 8·6% people; table 2) and in changes of 
classiﬁcations from mild to moderate dependence (2·6%). This also produced better 
agreement with DSM-IV and ICD classiﬁcations. Given that tolerance and withdrawal will 
often occur on chronic administration of opioids, the architects of DSM-5 have taken the 
approach that these criteria are not necessarily pathognomonic for pharmaceutical opioid 
dependence in the context of chronic opioid therapy. Our ﬁndings provided some suggestive 
evidence in support of this approach in that the model ﬁt was slightly better, and there was 
better agreement between DSM-5 and the other deﬁnitions with use of this deﬁnition. 
However, there are other ways of making a decision that these symptoms could be 
considered as symptoms of a use disorder. For example, tolerance and withdrawal, if 
endorsed, might alternatively be counted as criteria if a patient also has non-physiological 
adaptation symptoms, which as we reported earlier, did load more strongly in the model. 
Field testing of some of these possible changes with varied groups of patients might be 
helpful in shedding light on some of these possibilities. 
DSM-5 did not agree very well with the other classiﬁ- cations studied. Superﬁcially, the 
changes are only a minor broadening of criteria for opioid use disorders compared with 
other classiﬁcation systems (for moderate to severe DSM-5 use disorder, there was about 
an extra 2% of individuals). There were, however, only poor to fair κ values between DSM-5 
use disorder, and both DSM-IV and ICD-10 dependence (κ<0·6). Even when the grouping 
was limited to include only DSM-5 participants with 
moderate or severe use disorder (with or without conditional restrictions on the inclusion of 
tolerance and withdrawal), there were only marginal improvements in agreement with 
DSM-IV dependence, ICD-10 dependence, and ICD-11 dependence. 
There is little evidence for how to assess opioid use disorders in people prescribed opioids 
for pain (panel). Which domains are most important, and what language is the most 
appropriate to identify the phenomenon of addiction, is not clear. DSM-5 has taken into 
consideration the common physiological adaptations that occur with chronic opioid 
treatment (tolerance and withdrawal). Our ﬁndings provide some support for this approach, 
in that it resulted in a better model ﬁt (appendix). However, we show clear diﬀerences 
between the approach used by DSM-5, and all other approaches to classiﬁcation in this 
study. DSM-5 did not agree well with any of the other systems, and had the poorest model 
ﬁt (appendix). It should be noted, however, that these symptoms for physiological 
indications of dependence typically produced the poorest ﬁt to the dependence syndrome. 
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Our work suggests that care needs to be taken in identiﬁcation of this syndrome, and 
inquiry about these symptoms in clinical and structured interview schedules. The diagnosis 
of a use disorder as opposed to dependence also raises medico-legal issues. In many 
jurisdictions, individuals need to be diagnosed as meeting criteria for dependence to be 
eligible for opioid substitution therapy, or for opioid analgesic patients diagnosed as 
dependent to be eligible for different opioid regulatory requirements. It is not clear how this 
issue would be addressed within the DSM-5 classification–eg, should all people meeting 
criteria for a use disorder be deemed eligible? Should this eligibility be limited to individuals 
who meet criteria for moderate or severe DSM-5 use disorder? If all people who meet 
criteria for use disorder are eligible for substitution therapy, then it is clear that, at least in 
our cohort, this population would double. This change raises many issues; on one hand, the 
feasibility of provision of increased treatment coverage, the costs to patients and 
government, and the expansion of the number of patients with chronic pain receiving 
opioids for their pain who might be given an additional stigmatising label of “addicted”. On 
the other hand, a lower threshold would allow earlier identiﬁcation of problems and allow 
more patients to beneﬁt from interventions that prevent adverse events related to 
unintended dose escalation and poorer treatment outcomes. If only individuals with 
moderate or severe DSM-5 use disorder are eligible, then our study shows that many people 
who would be classiﬁed as dependent according to ICD or DSM-IV would not be classiﬁed as 
having a moderate 
or severe use disorder under DSM-5. 
The draft ICD-11 classiﬁcation seems to have moved in the opposite direction to DSM-5. We 
showed that the 
reduction in number of criteria classiﬁed similar proportions of patients as dependent as did 
ICD-10 and DSM-IV, while it also had the best model ﬁt (appendix). The additional 
advantage of having fewer, simpler criteria might include better identiﬁcation and more 
reliable diagnosis of dependence by clinicians working in a range of medical specialties. 
A clear strength of our study is the scope of our recruitment: 93% of Australian community 
pharmacies were approached, and a third assisted with recruitment; the geographic spread 
of participants was also similar to the spread of the Australian population.52 However, we 
might not have recruited a representative sample of people prescribed opioids for their 
chronic pain. To investigate this possibility, during recruitment we gathered additional data 
from a random sample of recruiting pharmacies (71 pharmacies) on the characteristics of 
their customers taking opioids during the 6 week recruitment window of their involvement. 
Of customers recorded as purchasing opioids in these pharmacies, 52% were women (POINT 
cohort was 55%); and 7% aged 18–34 years, 55% aged 
35–64 years, and 38% 65 years and older (vs 5%, 62%, and 33%, respectively, in POINT). Of 
these individuals, 63% were prescribed oxycodone (vs 62% in POINT), 17% prescribed 
morphine (vs 15% in POINT), 21% prescribed fentanyl patches (vs 15% in POINT) and 24% 
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buprenorphine patches (vs 21% in POINT). Although we cannot be sure that all the opioid 
customers recorded by these pharmacists had been taking these opioids for chronic pain 
and for 6 weeks or more, the similarity in these demographic and opioid prescription 
characteristics is reassuring. Another limitation is the potential biases that might be 
introduced by the reliance on self-report data. However, we used a well validated 
structured diagnostic clinical interview to ascertain symptoms of opioid dependence. Self-
report of substance use behaviours is also reliable when conﬁdentiality is assured and there 
are no disincentives for being honest,55, 56 as was the case in this study. 
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